26 August 2019 - Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. 

Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics.

To see why a little background is needed.

Read Forbes article